Antineoplastic Agents, Phytogenic
"Antineoplastic Agents, Phytogenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Concept/Terms
Antineoplastic Agents, Phytogenic- Antineoplastic Agents, Phytogenic
- Agents, Phytogenic Antineoplastic
- Phytogenic Antineoplastic Agents
- Antineoplastics, Phytogenic
- Phytogenic Antineoplastics
- Antineoplastics, Botanical
- Botanical Antineoplastics
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Phytogenic".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Phytogenic".
This graph shows the total number of publications written about "Antineoplastic Agents, Phytogenic" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Agents, Phytogenic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 5 | 0 | 5 |
1996 | 10 | 4 | 14 |
1997 | 7 | 5 | 12 |
1998 | 11 | 3 | 14 |
1999 | 14 | 4 | 18 |
2000 | 12 | 5 | 17 |
2001 | 8 | 5 | 13 |
2002 | 11 | 8 | 19 |
2003 | 8 | 3 | 11 |
2004 | 8 | 6 | 14 |
2005 | 16 | 6 | 22 |
2006 | 10 | 7 | 17 |
2007 | 6 | 6 | 12 |
2008 | 12 | 6 | 18 |
2009 | 6 | 7 | 13 |
2010 | 4 | 6 | 10 |
2011 | 12 | 12 | 24 |
2012 | 17 | 8 | 25 |
2013 | 14 | 11 | 25 |
2014 | 12 | 3 | 15 |
2015 | 16 | 7 | 23 |
2016 | 15 | 9 | 24 |
2017 | 9 | 5 | 14 |
2018 | 8 | 5 | 13 |
2019 | 8 | 6 | 14 |
2020 | 10 | 3 | 13 |
2021 | 4 | 4 | 8 |
2022 | 2 | 0 | 2 |
2023 | 2 | 0 | 2 |
Below are the most recent publications written about "Antineoplastic Agents, Phytogenic" by people in Profiles.
-
High dose, dual-release polymeric films for extended surgical bed paclitaxel delivery. J Control Release. 2023 Nov; 363:682-691.
-
Patient' and social aspects related to complementary mistletoe therapy in patients with breast cancer: A systematic review commissioned by the German agency for Health Technology Assessment. Eur J Oncol Nurs. 2023 Aug; 65:102338.
-
Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death. Mol Cancer Ther. 2022 11 03; 21(11):1663-1673.
-
Ultra-high drug loading improves nanoparticle efficacy against peritoneal mesothelioma. Biomaterials. 2022 06; 285:121534.
-
Bisdemethoxycurcumin Induces Cell Apoptosis and Inhibits Human Brain Glioblastoma GBM 8401/Luc2 Cell Xenograft Tumor in Subcutaneous Nude Mice In Vivo. Int J Mol Sci. 2022 Jan 04; 23(1).
-
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Coll Cardiol. 2021 11 02; 78(18):1768-1778.
-
Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions. J Clin Oncol. 2021 11 10; 39(32):3583-3590.
-
Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study. JAMA Intern Med. 2021 08 01; 181(8):1071-1080.
-
Uncomfortably numb: how Nav1.7 mediates paclitaxel-induced peripheral neuropathy. Brain. 2021 07 28; 144(6):1621-1623.
-
Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7. Brain. 2021 07 28; 144(6):1727-1737.